口服固态製剂契约製造市场（按剂型、治疗领域、应用、阶段和客户类型划分）－2025-2032年全球预测

预计到 2032 年，口服固态製剂契约製造市场规模将达到 877 亿美元，复合年增长率为 8.95%。

关键市场统计数据
基准年2024年	441.6亿美元
预计年份：2025年	482亿美元
预测年份 2032	877亿美元
复合年增长率 (%)	8.95%

本书简明扼要地全面介绍了当前影响口服固态製剂契约製造的动态因素及其对相关人员的战略意义。

口服固体製剂契约製造产业处于药物创新、复杂供应链和严格监管的交汇点，要求相关人员在保持敏捷性的同时，确保产品品质毫不妥协。本执行摘要概述了影响生产力计画开发平臺的扩展和客户需求的日益多样化，药物受託製造製造商正从单纯的生产合作伙伴转型为提供製剂专业知识、法规知识和生命週期管理支援的策略合作伙伴。

要了解这一格局，就需要清楚地理解产品形式和治疗重点如何影响生产的复杂性，临床和商业阶段如何改变需求模式，以及从生物技术创新者到成熟的製药公司和营养保健品製造商等不同类型的客户如何影响服务期望。本导言确立了贯穿整个报告的分析视角：将技术能力评估与商业策略和供应链风险管理结合。它也强调了决策者必须采用以证据为基础的外包方法，权衡专业化带来的好处与供应商网路集中化和不断变化的贸易政策所带来的风险。本执行摘要的其余部分将这些考虑转化为采购、营运、监管事务和业务拓展等部门领导者可操作的见解。

分析正在重新定义受託製造产能、品质期望和伙伴关係模式的变革性技术、监管和供应链转变。

口服固体製剂契约製造领域正经历一系列变革时期的驱动力来自技术进步、监管要求以及不断变化的客户需求。连续生产和先进的製程控制系统正从试点检验走向成熟，最终成为经过验证的生产路线，从而提高了产量并加强了对关键品质属性的控制。同时，生产营运的数位化，包括电子批记录、预测性维护和高级分析，正在彻底改变产能监控、偏差管理以及向监管机构提交证据的方式。这些技术驱动的改进正在催生新的伙伴关係模式，在这种模式下，製造商提供的不再是单一批次的生产名额，而是整合的开发和规模服务。

法律规范也在不断发展，监管机构更加重视即时产品品质保证和生命週期数据，以证明产品的稳健性和可追溯性。这种监管力度的加强提升了整合资料生态系统的价值，并增强了能够证明端到端品管能力的製造商的议价能力。此外，复杂配方和多颗粒技术的兴起正在推动服务产品方面的技术差异化，并促使契约製造製造商有选择地投资于专业能力。同时，客户的期望也在改变：生技公司寻求敏捷、以研发为中心的合作伙伴；大型製药公司优先考虑具有长期合作关係、合规且拥有成熟全球分销能力的供应商；而营养保健品客户则优先考虑成本效益和上市速度。这些因素的相互作用正在重新定义策略受託製造合作伙伴的意义，加速整合、能力专业化和联合商业化模式的形成。

评估2025年美国关税政策变化对采购、成本结构、供应链韧性和策略采购选择的累积影响

美国推出的2025年关税政策对口服固体製剂契约製造原料药和某些资本设备的进口成本竞争力，迫使许多生产商及其客户重新评估其供应商布局和库存策略。一些公司采取的直接应对措施包括：透过多元化采购管道、建立关键原材料的库存缓衝以及评估近岸外包和回流生产方案来降低跨境成本波动风险。然而，这些战术性措施需要在营运成本实力和供应链弹性之间做出权衡。

除了采购之外，关税引发的投入成本波动也影响配方开发和製程选择等上游决策。各团队越来越倾向于选择能够最大限度减少关税敏感成分使用或允许在不影响稳定性或性能的前提下进行替代的配方和辅料组合。同时，受託製造製造商正在投资供应链映射和双重筹资策略，以降低集中采购的风险。关税也凸显了物流优化、分类准确性和自由贸易区利用在控製到岸成本的战略重要性。展望未来，营运韧性将不再仅依赖单一的成本优势，而是更取决于能否将采购弹性、材料替代的法规遵循以及透明的供应商关係整合到一个连贯的风险缓解体系中。

细分市场主导的洞察揭示了产品形态、治疗用途、应用、开发阶段和客户类型如何影响您整个合约受託製造业务的服务需求。

在口服固体製剂契约製造中，细分市场层面的动态变化对于理解需求驱动因素和产能要求至关重要。胶囊分为硬胶囊和软胶囊，颗粒分为即时释和缓释，丸剂分为包衣丸剂和多颗粒丸剂，药片分为包衣片剂和非包衣片剂，因此需要采用不同的生产策略。这些剂型製剂形式因素决定了资本投资、分析测试的范围以及稳定性试验的复杂程度，进而影响哪些研发公司更适合进行研发，哪些公司更适合进行大规模商业性化生产。

抗感染疾病项目，包括抗生素和抗病毒药物，通常强调快速放大生产规模和严格的效力控制；而针对高血脂症和高血压的心血管药物组合则需要缓释和高稳定性。中枢神经系统治疗需要低剂量精准製剂以及控制释放忧郁症和抗癫痫製剂；而消化器官系统治疗，例如胃酸抑制剂和促动力药，则需要考虑独特的溶出度和生物製药特性。肿瘤治疗，无论是针对血液肿瘤或固态肿瘤，都需要专门的隔离措施、监管链计划以及以病人安全为中心的品质系统。此外，临床阶段和商业化阶段计划之间的差异决定了灵活性和检验性之间的平衡。最后，客户类型也会影响合作模式。生技公司通常需要客製化的开发支援和灵活的反应速度；营养保健品客户优先考虑成本效益高的生产和快速上市；而製药客户则重视长期供应的可靠性和全球监管的协调性。这些细分为技术投资、商业性定位和伙伴关係关係设计与客户特定需求的协调提供了一个框架。

区域战略视角展现了美洲、欧洲、中东和非洲以及亚太地区的动态变化如何重塑製造业布局、物流和监管格局。

每个地区的市场动态差异显着，并影响製造布局、监管策略和物流方面的策略选择。在美洲，製造商受益于毗邻大型商业市场和响应迅速的分销网络，但也面临严格的监管审查和竞争压力，需要针对特定产品类别实现本地化生产。该地区通常是后期商业供应和项目的首选地，这些项目对上市时间和快速补货能力要求极高，因此，该地区支撑着一种强调经过检验的大规模製造能力和先进品质系统的模式。

欧洲、中东和非洲地区是一个多元化的市场环境，监管环境各异，定价机制分散，因此需要先进的监管情报和灵活的分销计划。在该地区运营的製造商必须应对不同的核准途径、不同的监管时间表以及影响临床和商业批次生产地点的区域贸易协定。该地区的产能投资通常包括模组化设施和完善的药物安全检测基础设施，以支持跨国上市和核准后的承诺。

亚太地区在製剂研发、成本优势製造以及快速发展的分析和法规专业知识方面拥有强大的实力，仍然是研发阶段工作和散装生产的战略中心。然而，该地区的企业必须权衡成本优势与日益增长的品质保证、资料完整性和符合国际法规标准的期望。供应链韧性因素，包括港口吞吐能力和地缘政治风险，在亚太地区的采购决策和全球专案的库存布局选择中发挥关键作用。

竞争情报：透过摘要领先合约製造公司的策略重点、能力投资和伙伴关係方式，来描述它们的特征。

领先的合约研究公司凭藉着深厚的技术实力、全面的开发服务和可靠的监管记录脱颖而出。领先的供应商会选择性地投资于灵活的生产平台，这些平台能够检验各种固态剂型的生产能力，同时保持严格的数据完整性和品质保证系统。他们通常将产能投资与配方优化、分析方法开发和稳定性研究等相关服务相结合，使客户能够顺利地从临床批次过渡到商业化生产，而无需重复的供应商交接。

高绩效公司的另一个大标誌是其清晰明确的伙伴关係模式，这种模式将奖励与客户成功紧密结合。这些模式包括透明的成本结构、规模化生产的风险共用机制，以及诸如法规文件支援和序列化准备等附加价值服务。对数位化营运的投资，例如即时批次分析、整合品管系统和先进的供应链视觉化工具，也使领先企业区别于普通商品供应商。此外，那些为辅料、包装和专用模具构建强大供应商生态系统的公司，更有能力应对市场波动，并提供可靠的前置作业时间。儘管策略併购和联盟仍然是扩大产能的途径，但最重要的竞争优势仍然是：能够大规模地提供可预测的质量，透过创新解决配方难题，并在产品生命週期内提供咨询和支援。

为行业领导者提供切实可行的建议，以加快韧性建设、提高效率、抓住新的商机，并使营运与不断变化的客户和监管需求保持一致。

行业领导者可以透过制定一系列有针对性的营运和商业优先事项，将他们的观点转化为实际行动。首先，他们投资于模组化、灵活的生产平台，以支援胶囊、颗粒、丸剂和片剂生产之间的快速切换，同时保持有效的品管。同时，他们提升配方和分析服务，以支持从低剂量中枢神经系统製剂到需要特殊密闭和稳定性通讯协定的肿瘤製剂等复杂的治疗领域。拥有这些能力将缩短研发週期，并提升他们作为长期伙伴关係伙伴的吸引力。

第二，我们将透过实施关键辅料的双源筹资策略和利用短期库存策略来增强采购和规划中的供应链韧性，尤其针对对关税敏感的投入品。我们将利用先进的采购分析和供应商绩效监控来强化此策略，以便及早发现并消除漏洞。第三，我们将优先投资于监管和资料完整性的改进，以促进跨国申报和即时品质监控，包括增强电子批次记录、序列化和监管文件编制能力。第四，我们将优化商业性服务，包括基于绩效的伙伴关係模式和整合从研发到商业化的过渡服务，从而协调奖励并减少客户摩擦。最后，我们将制定数位转型蓝图，将生产分析、预测性维护和品质指标与经营团队仪錶板连接起来。

详细的调查方法，包括一手和二手检验、同行验证、品管以及分析框架，以确保严谨的洞察力和可重复性。

本执行摘要的调查方法整合了多个资料流和检验通讯协定，以确保分析的严谨性和实际应用价值。主要研究包括对製造外包及其客户群的技术负责人、品质主管、供应链经理和研发主管进行结构化访谈。这些访谈提供了关于能力投资、商业重点以及监管和贸易发展对其营运影响的第一手资讯。次要研究则利用监管指南、专利申请、临床试验註册资讯和开放原始码企业资料，整合观察到的趋势并识别能力布局的变化。

数据综合采用了三角验证法，将定性见解与已记录的监管行动和观察到的能力投资进行匹配。分析框架包括能力映射、供应链脆弱性评估和合作伙伴原型构建，从而能够将分散的讯号转化为连贯的策略意义。品管包括专家同侪审查、调查方法（审核确保研究结果的可重复性）以及敏感性检查（以评估结论对其他解释的稳健性）。在整个研究过程中，重点在于产生反映营运实际情况和监管限制的可操作情报，同时保持资料来源和得出建议的推理步骤的透明度。

对口服固体製剂生产中的战略要务、风险考量以及投资和营运调整的优先领域进行总结性综合分析

这份高阶主管总结报告重点阐述了口服固体製剂契约製造领域相关人员面临的几项共同要务。技术差异化、营运灵活性和供应链韧性将日益决定哪些供应商能够赢得战略合同，哪些客户能够获得可靠的供应。随着连续生产、数位化品质系统和先进製剂技术从早期采用者发展成为行业标准，受託製造製造商的价值提案取决于其能否将这些能力整合到一个连贯的、面向客户的服务模式中。监管机构对可追溯性和即时品质保证的要求进一步推动了战略要务，因此需要投资于能够支援合规性和营运改进的数据系统。

对于决策者而言，未来发展之路需要在选择性资本配置和伙伴关係驱动型创新之间取得平衡。投资模组化製造和相关开发服务可以增强选择余地，而加强筹资策略和地理多元化则可以降低关税和物流风险。最终，那些能够将卓越的技术和咨询能力相结合，帮助客户将配方科学转化为可扩展且符合监管要求的生产模式的企业，将最有可能赢得长期伙伴关係关係。本竞争考察摘要旨在为采购、营运、监管事务和业务拓展等领域提供切实可行的后续步骤，并为将结构性趋势转化为竞争优势和营运韧性提供蓝图。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 采用连续生产技术加速口服固体製剂的生产并降低批次差异
• 在契约製造工厂实施先进的数位双胞胎和即时製程分析技术（PAT）监控，以提高品管。
• 为满足个人化医疗的需求，特殊缓释性和标靶口服固体製剂的需求激增。
• 扩大外包设施中高活性药物成分的产能，以满足肿瘤治疗需求
• 将绿色化学原则和永续辅料采购融入口服固态製剂生产营运中
• 製药创新者与合约生产商之间的策略联盟，旨在共同开发和技术转移复杂的口服固体製剂
• 监管机构对序列化和可追溯性合规性的重视，正在推动对智慧包装解决方案的投资。
• 发展自动化端到端连续製粒和压片系统以提高生产效率
• 儿科和孤儿药口服固体製剂需求的不断增长，催生了对专业契约製造服务的需求。
• 投资于数位化供应链韧性和替代采购管道，以减轻疫情后固态口服製剂供应中断的影响

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 口服固态契约製造市场（依剂型划分）

• 胶囊
  • 硬明胶
  • 软明胶
• 颗粒
  • 即时发布
  • 修復版本
• 颗粒
  • 包衣颗粒
  • 多粒子
• 药片
  • 涂层
  • 未涂层

9. 依治疗领域分類的口服固态契约製造市场

• 抗感染药物
  • 抗生素
  • 抗病毒药物
• 心血管系统
  • 高血脂症
  • 高血压
• 中枢神经系统
  • 忧郁症
  • 癫痫
• 消化器官系统
  • 制酸剂
  • 促动力药
• 肿瘤学
  • 血液学
  • 固态肿瘤

第十章 依应用分類的口服固态製剂契约製造市场

• 在商店
• 处方药

第十一章 口服固态契约製造市场（依阶段划分）

• 临床试验
• 商业的

第十二章 依客户类型分類的口服固态契约製造市场

• 生物技术
• 营养补充品
• 製药

第十三章：各地区口服固态製剂契约製造市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 口服固态製剂契约製造市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

15. 各国口服固态製剂契约製造市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Lonza Group AG
  • Recipharm AB
  • Siegfried Holding AG
  • Fareva SA
  • PCI Pharma Services, Inc.
  • Aurobindo Pharma Limited
  • Ajinomoto Bio-Pharma Services, LLC
  • Piramal Pharma Limited

The Oral Solid Dosage Contract Manufacturing Market is projected to grow by USD 87.70 billion at a CAGR of 8.95% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 44.16 billion
Estimated Year [2025]	USD 48.20 billion
Forecast Year [2032]	USD 87.70 billion
CAGR (%)	8.95%

A concise but comprehensive introduction that frames the current dynamics shaping oral solid dosage contract manufacturing and strategic relevance to stakeholders

The oral solid dosage contract manufacturing sector sits at the intersection of pharmaceutical innovation, complex supply chains, and stringent regulatory regimes, requiring stakeholders to balance agility with uncompromising quality. This executive summary introduces the landscape by outlining the structural drivers that dictate capacity planning, formulation strategy, and partner selection, and by framing the competitive tensions between speed-to-market and long-term operational resilience. As development pipelines broaden and customer needs diversify, contract manufacturers are transitioning from pure production partners to strategic collaborators who contribute formulation expertise, regulatory know-how, and lifecycle management support.

Understanding the forces at play requires a clear view of how product form and therapeutic focus inform manufacturing complexity, how clinical and commercial stages alter demand patterns, and how customer types-ranging from biotechnology innovators to established pharmaceutical companies and nutraceutical producers-shape service expectations. This introduction establishes the analytical lens used throughout the report: one that integrates technical capability assessment with commercial strategy and supply chain risk management. It also highlights the imperative for decision-makers to adopt an evidence-based approach to outsourcing that weighs the benefits of specialization against the vulnerabilities introduced by concentrated supplier networks and evolving trade policies. The remainder of this executive summary translates these observations into actionable insights for procurement, operations, regulatory affairs, and business development leaders.

An analysis of transformative technological, regulatory, and supply chain shifts redefining capacity, quality expectations, and partnership models in contract manufacturing

The contract manufacturing landscape for oral solid dosage forms is undergoing a series of transformative shifts driven by converging technological advances, regulatory expectations, and changing client demands. Continuous manufacturing and advanced process control systems are maturing from pilot demonstrations into validated production routes, enabling improved throughput and tighter control of critical quality attributes. At the same time, digitalization of manufacturing operations-covering electronic batch records, predictive maintenance, and advanced analytics-reshapes how capacity is monitored, deviations are managed, and regulatory evidence is compiled. These technology-enabled improvements are leading to new partnership models in which manufacturers offer integrated development and scale-up services rather than discrete batch production slots.

Regulatory frameworks are also evolving, with agencies prioritizing real-time product quality assurance and lifecycle data that demonstrate robustness and traceability. This regulatory emphasis increases the value of integrated data ecosystems and strengthens the negotiating position of manufacturers that can demonstrate end-to-end quality controls. Moreover, the rise of complex formulations and multiparticulate technologies adds technical differentiation to service offerings, pushing contract manufacturers to invest selectively in specialized capabilities. Concurrently, customer expectations are shifting: biotechnology firms seek nimble, development-focused partners; large pharmaceutical companies prioritize long-term, compliant suppliers with proven global distribution capabilities; and nutraceutical customers emphasize cost efficiency and rapid market access. The interaction of these factors is prompting a redefinition of what it means to be a strategic contract manufacturing partner and is accelerating consolidation, capability specialization, and collaborative commercialization models.

An assessment of the cumulative effects of United States tariff policy changes in 2025 on sourcing, cost structures, supply chain resilience, and strategic sourcing choices

The 2025 tariff environment introduced by the United States has produced layered implications across sourcing choices, unit cost structures, and contingency planning for contract manufacturing of oral solid dosage forms. Tariff adjustments have affected the cost competitiveness of importing intermediate excipients, active pharmaceutical ingredients, and certain capital equipment, prompting many manufacturers and their customers to reassess supplier footprints and inventory strategies. For some organizations, the immediate response has been to diversify procurement channels, build inventory cushions for critical raw materials, and evaluate nearshoring or reshoring alternatives to reduce exposure to cross-border cost volatility. These tactical moves, however, entail trade-offs between working capital intensity and supply chain flexibility.

Beyond procurement, tariff-induced input cost variability is influencing upstream decisions in formulation development and process selection. Teams are increasingly favoring formulations and excipient sets that minimize exposure to tariff-sensitive components or that permit substitution without compromising stability or performance. In parallel, contract manufacturers are investing in supply chain mapping and dual-sourcing strategies to mitigate single-point-of-failure risks. The tariffs also elevate the strategic importance of logistics optimization, classification accuracy, and free trade zone utilization as levers to manage landed costs. Looking forward, operational resilience will depend less on single cost advantages and more on the ability to integrate procurement agility, regulatory compliance for material substitutions, and transparent supplier relationships into a coherent risk-mitigation posture.

Segment-driven insights revealing how form, therapeutic focus, application, development stage, and customer type influence service demands across contract manufacturing operations

Segment-level dynamics are central to understanding demand drivers and capability requirements across oral solid dosage contract manufacturing. When form type considerations are front and center, capsules present distinct supply chain and tooling requirements compared to tablets; capsules can be segmented into hard gelatin and soft gelatin variants, while granules carry immediate release and modified release considerations, pellets require coated pellet or multiparticulate expertise, and tablets demand differentiated approaches for coated and uncoated configurations. These form-specific factors determine equipment investments, analytical testing scope, and stability program complexity, and they influence which providers are suited to development versus high-volume commercial work.

Therapeutic area focus further shapes service profiles, with anti-infective programs spanning antibiotics and antivirals that often emphasize rapid scale-up and stringent potency controls, and cardiovascular portfolios addressing hyperlipidemia and hypertension with long-term release and high-stability demands. Central nervous system therapies bring requirements for low-dose precision and controlled-release depression or epilepsy formulations, while gastrointestinal treatments such as acid reducers and prokinetics impose unique dissolution and biopharmaceutic considerations. Oncology work, whether hematological or solid tumor-directed, requires specialized containment, chain-of-custody processes, and patient-safety-focused quality systems. Application orientation-over-the-counter versus prescription-affects regulatory pathways, labeling, and shelf-life expectations, and the distinction between clinical trial-stage and commercial-stage projects determines the balance between flexibility and validated repeatability. Finally, customer type influences engagement models: biotechnology companies often require bespoke development support and agility, nutraceutical clients prioritize cost-efficient production and rapid time-to-shelf, and pharmaceutical customers emphasize long-term supply reliability and global regulatory harmonization. Taken together, these segmentation dimensions provide a framework for aligning technical investments, commercial positioning, and partnership design to client-specific needs.

Regional strategic outlook describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics are reshaping manufacturing footprints, logistics, and regulatory navigation

Regional dynamics vary considerably and shape strategic choices for manufacturing footprint, regulatory strategy, and logistics. In the Americas, manufacturers benefit from proximity to large commercial markets and rapid-response distribution networks, but they also face stringent regulatory scrutiny and competitive pressure to localize production for certain product classes. This region is often chosen for late-stage commercial supply and for programs where time-to-market and rapid replenishment capabilities are critical, and it supports models that emphasize validated large-scale capacity and advanced quality systems.

Europe, Middle East & Africa present a multifaceted environment in which regulatory heterogeneity and fragmented pricing landscapes require sophisticated regulatory intelligence and flexible distribution planning. Manufacturers operating in this region must navigate diverse approval pathways, varying regulatory timelines, and regional trade agreements that influence where clinical and commercial batches are produced. Capability investments here often include modular facilities and robust pharmacovigilance infrastructures to support multinational launches and post-approval commitments.

Asia-Pacific remains a strategic hub for both development-stage work and volume manufacturing, offering extensive capabilities in formulation development, cost-competitive production, and rapidly expanding analytical and regulatory expertise. However, companies in this region must balance cost advantages with growing expectations around quality assurance, data integrity, and compliance with international regulatory standards. Supply chain resilience considerations, including port capacities and geopolitical risks, play a prominent role in regional sourcing decisions and in choices about inventory positioning for global programs.

Competitive intelligence summarizing the strategic priorities, capability investments, and partnership approaches that distinguish leading contract manufacturing organizations

Leading contract manufacturers distinguish themselves through a combination of deep technical capabilities, integrated development services, and demonstrated regulatory track records. Top-tier providers invest selectively in flexible production platforms that can be validated across a range of solid dosage forms while maintaining rigorous data integrity and quality assurance systems. They commonly pair capacity investments with adjacent services such as formulation optimization, analytical method development, and stability sciences, enabling clients to transition smoothly from clinical batches to commercial throughput without redundant vendor handoffs.

Another characteristic of high-performing firms is a clear articulation of partnership models that align incentives with client success. This includes transparent cost structures, shared risk arrangements for scale-up, and value-added services such as regulatory dossier support and serialization readiness. Investments in digital operations-real-time batch analytics, integrated quality management systems, and advanced supply chain visibility tools-also segregate leaders from commodity providers. Additionally, firms that cultivate robust supplier ecosystems for excipients, packaging, and specialized tooling are better positioned to manage disruptions and offer reliable lead times. Strategic M&A and alliance activity continue to be vehicles for capability expansion, but the most consequential competitive differentiators remain the ability to deliver predictable quality at scale, to innovate around formulation challenges, and to provide consultative support across product lifecycles.

Actionable recommendations for industry leaders to accelerate resilience, drive efficiency, capture new opportunities, and align operations with evolving customer and regulatory needs

Industry leaders can purposefully translate insight into action by adopting a set of targeted operational and commercial priorities. First, invest in modular, flexible manufacturing platforms that support rapid changeover between capsules, granules, pellets, and tablet production while preserving validated quality controls; this approach lowers barrier-to-entry for diverse programs and accelerates response to shifting client pipelines. Concurrently, strengthen formulation and analytical services to support complex therapeutic areas, from low-dose CNS products to oncology formulations requiring specialized containment and stability protocols. These capabilities reduce time-to-scale and increase the attractiveness of a provider for long-term partnerships.

Second, embed supply chain resilience into procurement and planning by instituting dual-sourcing strategies for critical excipients and leveraging near-term inventory strategies for tariff-sensitive inputs. Augment this with advanced procurement analytics and supplier performance monitoring to detect and remediate vulnerabilities early. Third, prioritize regulatory and data integrity investments that facilitate multinational submissions and real-time quality monitoring, including expanded capabilities for electronic batch records, serialization, and regulatory dossier compilation. Fourth, refine commercial offerings to include outcome-based partnership models and bundled development-to-commercial transition services that align incentives and reduce client friction. Finally, cultivate a digital transformation roadmap that links production analytics, predictive maintenance, and quality metrics to executive dashboards; this enables faster decision cycles, clearer capacity signaling, and demonstrable compliance during audits.

Robust research methodology detailing primary and secondary data collection, expert validation, quality controls, and analytical frameworks used to ensure rigorous insights and reproducibility

The research approach underpinning this executive summary integrates multiple data streams and validation protocols to ensure analytical rigor and practical relevance. Primary research included structured interviews with technical leaders, quality heads, supply chain managers, and business development executives across contract manufacturers and their customer base. These discussions provided first-hand perspectives on capability investments, commercial priorities, and the operational impacts of regulatory and trade developments. Secondary research drew on public regulatory guidance, patent filings, clinical trial registries, and open-source corporate disclosures to contextualize observed trends and identify shifts in capability footprints.

Data synthesis employed triangulation techniques that cross-checked qualitative insights with documented regulatory actions and observed capacity investments. Analytical frameworks included capability mapping, supply chain vulnerability assessment, and partner archetype development, which together enabled the translation of disparate signals into coherent strategic implications. Quality controls involved peer review by subject-matter experts, methodology audits to verify reproducibility of findings, and sensitivity checks to assess the robustness of conclusions against alternative interpretations. Throughout the research process, emphasis was placed on producing actionable intelligence that reflects operational realities and regulatory constraints while maintaining transparency about data sources and the inferential steps taken to derive recommendations.

Concluding synthesis that crystallizes strategic imperatives, risk considerations, and priority areas for investment and operational adaptation in oral solid dosage manufacturing

This executive synthesis highlights several convergent imperatives for stakeholders in oral solid dosage contract manufacturing. Technical differentiation, operational flexibility, and supply chain resilience will increasingly determine which providers win strategic engagements and which clients secure dependable supply. As continuous manufacturing, digital quality systems, and advanced formulation capabilities migrate from early adopters to industry norms, the value proposition of contract manufacturers will rest on the ability to integrate these capabilities into coherent, client-facing service models. Regulatory demands for traceability and real-time quality assurance add another layer of strategic necessity, requiring investment in data systems that support both compliance and operational improvement.

For decision-makers, the path forward requires balancing selective capital allocation with partnership innovation. Investing in modular production and adjacent development services builds optionality, while enhanced procurement strategies and geographic diversification mitigate tariff and logistics risks. Ultimately, organizations that combine technical excellence with consultative engagement-helping clients translate formulation science into scalable, regulatorily defensible production-will be best positioned to capture long-term partnerships. The insights in this summary aim to inform pragmatic next steps across procurement, operations, regulatory affairs, and business development, offering a roadmap for converting structural trends into competitive advantage and operational resilience.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of continuous manufacturing technologies to accelerate oral solid dosage production and reduce batch variability
• 5.2. Implementation of advanced digital twins and real-time PAT monitoring in contract manufacturing facilities for improved quality control
• 5.3. Surge in specialty modified-release and targeted oral solid dosage formulations to meet personalized medicine demands
• 5.4. Expansion of high-potency active pharmaceutical ingredient handling capabilities in outsourcing facilities to address oncology therapies
• 5.5. Integration of green chemistry principles and sustainable excipient sourcing in oral solid dosage manufacturing operations
• 5.6. Strategic alliances between pharma innovators and CMOs for co-development and tech transfer of complex OSD formulations
• 5.7. Regulatory emphasis on serialization and track-and-trace compliance driving investment in smart packaging solutions
• 5.8. Growth of automated end-to-end continuous granulation and tableting systems to enhance production efficiency
• 5.9. Rising demand for pediatric and orphan drug oral solid formulations prompting specialized contract manufacturing services
• 5.10. Investments in digital supply chain resilience and alternative sourcing to mitigate post-pandemic oral solid dosage disruptions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Solid Dosage Contract Manufacturing Market, by Form Type

• 8.1. Capsules
  • 8.1.1. Hard Gelatin
  • 8.1.2. Soft Gelatin
• 8.2. Granules
  • 8.2.1. Immediate Release
  • 8.2.2. Modified Release
• 8.3. Pellets
  • 8.3.1. Coated Pellets
  • 8.3.2. Multiparticulate
• 8.4. Tablets
  • 8.4.1. Coated
  • 8.4.2. Uncoated

9. Oral Solid Dosage Contract Manufacturing Market, by Therapeutic Area

• 9.1. Anti Infectives
  • 9.1.1. Antibiotics
  • 9.1.2. Antivirals
• 9.2. Cardiovascular
  • 9.2.1. Hyperlipidemia
  • 9.2.2. Hypertension
• 9.3. Central Nervous System
  • 9.3.1. Depression
  • 9.3.2. Epilepsy
• 9.4. Gastrointestinal
  • 9.4.1. Acid Reducers
  • 9.4.2. Prokinetics
• 9.5. Oncology
  • 9.5.1. Hematological
  • 9.5.2. Solid Tumor

10. Oral Solid Dosage Contract Manufacturing Market, by Application

• 10.1. Over The Counter
• 10.2. Prescription Drugs

11. Oral Solid Dosage Contract Manufacturing Market, by Stage

• 11.1. Clinical Trial
• 11.2. Commercial

12. Oral Solid Dosage Contract Manufacturing Market, by Customer Type

• 12.1. Biotechnology
• 12.2. Nutraceutical
• 12.3. Pharmaceutical

13. Oral Solid Dosage Contract Manufacturing Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Oral Solid Dosage Contract Manufacturing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Oral Solid Dosage Contract Manufacturing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Catalent, Inc.
  • 16.3.2. Thermo Fisher Scientific Inc.
  • 16.3.3. Lonza Group AG
  • 16.3.4. Recipharm AB
  • 16.3.5. Siegfried Holding AG
  • 16.3.6. Fareva SA
  • 16.3.7. PCI Pharma Services, Inc.
  • 16.3.8. Aurobindo Pharma Limited
  • 16.3.9. Ajinomoto Bio-Pharma Services, LLC
  • 16.3.10. Piramal Pharma Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MODIFIED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED PELLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPARTICULATE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY UNCOATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ACID REDUCERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 239. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 240. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 241. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
• TABLE 242. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025-2032 (USD MILLION)
• TABLE 243. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
• TABLE 244. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
• TABLE 245. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2018-2024 (USD MILLION)
• TABLE 246. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, 2025-2032 (USD MILLION)
• TABLE 247. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2018-2024 (USD MILLION)
• TABLE 248. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PELLETS, 2025-2032 (USD MILLION)
• TABLE 249. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
• TABLE 250. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
• TABLE 251. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 252. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 253. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 254. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 255. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
• TABLE 256. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
• TABLE 257. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
• TABLE 258. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
• TABLE 259. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
• TABLE 260. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
• TABLE 261. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 262. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 263. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 264. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 265. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
• TABLE 266. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
• TABLE 267. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
• TABLE 268. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2032 (USD MILLION)
• TABLE 269. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2018-2024 (USD MILLION)
• TABLE 272. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFA